High-dose progestin therapy for metastatic breast cancer
| Autor: | H. B. Muss, J. M. Cruz |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
CA15-3
Oncology Medroxyprogesterone medicine.medical_specialty medicine.drug_class Breast Neoplasms law.invention Breast cancer Randomized controlled trial law Internal medicine medicine Humans Medroxyprogesterone acetate Neoplasm Metastasis Gynecology business.industry Megestrol Acetate Megestrol Hematology medicine.disease Metastatic breast cancer Clinical trial Megestrol acetate Female business Progestin medicine.drug |
| Zdroj: | Annals of Oncology. 3:S15-S20 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/3.suppl_3.s15 |
| Popis: | Summary Progestin therapy has become an established endocrine modality for the treatment of metastatic breast cancer, with medroxyprogesterone acetate and megestrol acetate being the most widely used agents. Both drugs display similar effectiveness as initial and secondary therapy for pa tients with advanced disease, with combined complete and partial response rates of approximately 30% to 40%. Uncon trolled trials have suggested that high doses of medroxypro gesterone may be more effective than lower doses, but ran domized trials have yielded conflicting results. Clinical trials of megestrol acetate have demonstrated it to be an effective, well-tolerated oral progestin, and a recent randomized trial has suggested that higher megestrol acetate doses may be as sociated with not only improved response but also improved time to disease progression and survival. Further trials of high-dose megestrol acetate for both initial and secondary therapy are under way, and their results will provide valuable information concerning the role of such treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|